Iran’s Health Crisis Deepens as Sanctions, Inflation and War Strain Access to Medicine
For patients across Iran, the country’s economic crisis is increasingly becoming a healthcare crisis, with rising prices, shortages and financial instability making essential medicines harder to obtain.
TEHRAN — Iran’s economic deterioration is increasingly being felt inside pharmacies and hospitals, where patients suffering from chronic and serious illnesses are confronting higher medicine prices, shortages and growing difficulties accessing essential treatments.
The pressure comes as the country faces a combination of international sanctions, severe inflation, currency depreciation, disruptions to financial channels and damage to parts of its pharmaceutical infrastructure.
For patients who depend on medication every day, the consequences can be immediate.
Some medicines remain available but have become significantly more expensive. Others are increasingly difficult to find, forcing patients and their families to visit multiple pharmacies or search for alternatives. In some cases, families have reportedly resorted to borrowing money or selling personal belongings to pay for treatment.
The crisis is particularly concerning for people requiring continuous medication for conditions such as cardiovascular disease, diabetes, cancer and other chronic illnesses.
A pharmaceutical system under pressure
Iran has developed a substantial domestic pharmaceutical industry and produces the vast majority of the medicines consumed inside the country. However, domestic production does not eliminate dependence on international supply chains.
Pharmaceutical manufacturers still require imported raw materials, specialized equipment and other components. Certain complex or highly specialized treatments also need to be sourced from abroad.
Restrictions on access to foreign currency and international financial systems can therefore create difficulties even when medicines themselves are not directly prohibited.
This has contributed to a complicated situation in which products may be legally permitted to enter the country while companies face practical obstacles in financing, importing and distributing them.
The result is a supply chain under sustained pressure.
Inflation is changing the price of treatment
The depreciation of Iran’s currency has further intensified the problem.
As the rial loses purchasing power, imported pharmaceutical ingredients and medical equipment become more expensive. Those costs eventually affect manufacturers, distributors, pharmacies and, ultimately, patients.
The pharmaceutical sector has also been affected by delays in payments from insurance providers.
Thousands of private pharmacies have reportedly faced substantial outstanding payments, creating additional pressure on businesses that must purchase and maintain inventories while waiting for reimbursement.
For smaller pharmacies, prolonged delays can make it increasingly difficult to maintain stocks of medicines that patients depend on.
Patients caught between shortages and prices
The consequences are particularly serious for people who cannot simply stop treatment.
A patient with a chronic illness may be able to postpone purchasing a non-essential product. A person dependent on medication for heart disease, diabetes or another serious condition may not have that option.
When prices rise faster than household incomes, even medicines that remain technically available can become inaccessible.
The problem can also encourage patients to search for medicines through informal networks, relatives returning from abroad or other channels outside the conventional pharmaceutical system.
That creates additional concerns over authenticity, storage conditions and medical supervision.
War adds another layer of uncertainty
The pharmaceutical crisis has unfolded alongside military confrontation and damage to infrastructure.
Parts of Iran’s pharmaceutical and research sector have reportedly suffered damage during recent attacks, adding pressure to an already vulnerable system.
Damage to manufacturing facilities, research institutions, distribution centers and other infrastructure can have consequences well beyond the immediate physical destruction. Production interruptions can affect inventories weeks or months later, particularly when replacement equipment or imported components are difficult to obtain.
The country's healthcare system is therefore dealing with several interconnected problems rather than a single shortage.
Sanctions and humanitarian exemptions
The United States maintains that humanitarian goods such as food and medicine are exempt from its sanctions regime.
However, humanitarian exemptions do not necessarily eliminate every obstacle associated with international trade.
Banks, insurers, shipping companies and suppliers may still be reluctant to conduct transactions involving sanctioned jurisdictions because of the potential financial and regulatory risks.
This can make international transactions slower, more expensive or more complicated, even when the underlying product is permitted.
For patients, however, the distinction between a formal exemption and practical availability can be difficult to see.
What matters at the pharmacy counter is whether the medicine is there — and whether they can afford it.
A crisis with consequences beyond Iran
The economic pressure facing Iran is also connected to wider regional and global markets.
The country's role in the global energy system means that disruptions involving Iranian oil exports, shipping routes or the Strait of Hormuz can influence international energy prices and contribute to broader economic uncertainty.
Inside Iran, however, the consequences are more immediate and personal.
The combination of inflation, currency depreciation, sanctions, supply-chain disruptions and conflict is placing additional pressure on households already struggling to maintain their purchasing power.
For patients with serious illnesses, the issue is not simply economic.
It is whether treatment can continue.
As negotiations, sanctions and military developments dominate international headlines, Iran's healthcare system is becoming another measure of the cost of prolonged confrontation. Behind the statistics are patients trying to obtain prescriptions, families searching for affordable alternatives and pharmacists attempting to keep essential medicines on their shelves.
The humanitarian consequences of the crisis are therefore increasingly being experienced not only at the level of governments and financial markets, but in the most basic places of all: pharmacies, hospitals and homes.
Comments